Your cSSSI revenue is MINE!

[Anonymous]

Look, you can keep the bacteremia business since you have the data but ALL of the skin business is MINE, very very soon. I am getting everything in order. Antibiotic sub-committes, P&T, YOUR speakers, etc. They get it. $68.75 a day.

I know, I know - you are going to keep the ID business where you helped the ID build an infusion suite. I admit, I will not get that. But, all other skins business is mine.

I have already kicked Tygacil's ass. They are too scared to sell. Don't know what happened to them after the Pfizer merger, but the run scared.

I have started to kick Zyvox's ass. Easy. 1/3 the price for 3x the coverage.

But my real aim is set on the ridiculous amount of skin business Cubicin has. It will be like stealing from a baby.

Sit back and watch. Fight if you want. Nothing will help. Pin this thread and come back next year and I will have 90%+ of your revenue.

Better get up to speed on c.diff...........

 

[Anonymous]

Look, you can keep the bacteremia business since you have the data but ALL of the skin business is MINE, very very soon. I am getting everything in order. Antibiotic sub-committes, P&T, YOUR speakers, etc. They get it. $68.75 a day.

I know, I know - you are going to keep the ID business where you helped the ID build an infusion suite. I admit, I will not get that. But, all other skins business is mine.

I have already kicked Tygacil's ass. They are too scared to sell. Don't know what happened to them after the Pfizer merger, but the run scared.

I have started to kick Zyvox's ass. Easy. 1/3 the price for 3x the coverage.

But my real aim is set on the ridiculous amount of skin business Cubicin has. It will be like stealing from a baby.

Sit back and watch. Fight if you want. Nothing will help. Pin this thread and come back next year and I will have 90%+ of your revenue.

Better get up to speed on c.diff...........

Your quoted price is $42. p/vial. That comes to $84. p/day. Even with a standard 10% max discount/rebate, you can't get to $68.75. What do you plan to do about the rising ESBL rate that is occurring. In many areas it is 30-50%. And if you paid attention you would notice that Cubicin is loosing business due to their high price. Also, Zyvox is primarily used for MRSA pneumonia, and anyway you slice it Teflaro cannot compete with a pill for MRSA in the outpatient market. Everything about Teflaro depends on resistant gram (-) problems.